Welcome to our dedicated page for Acadia Pharmaceuticals SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand how Acadia reports its financial results, material events, and governance changes as it develops and commercializes medicines for neurological and rare diseases.
Acadia’s current reports on Form 8‑K include items such as quarterly and year‑to‑date financial results and updates on board composition. For example, the company has filed 8‑Ks to furnish press releases announcing results for the three and nine months ended September 30, 2025, and for the three and six months ended June 30, 2025, under Item 2.02 (Results of Operations and Financial Condition. Another 8‑K discloses the resignation of a member of the Board of Directors under Item 5.02, noting that the resignation was not due to any dispute or disagreement with the company or the Board.
In addition to 8‑Ks, Acadia files annual and quarterly reports that typically contain detailed discussions of its commercial portfolio, including NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE for Rett syndrome, as well as information on its pipeline programs in Alzheimer’s disease psychosis, Lewy body dementia psychosis, essential tremor, and other neuroscience and neuro‑rare indications. These filings generally address revenue composition, research and development spending, risk factors, and other information relevant to ACAD shareholders.
On Stock Titan, Acadia’s SEC filings are supplemented with AI-powered summaries that explain the key points of lengthy documents such as 10‑K annual reports, 10‑Q quarterly reports, and 8‑K current reports in plain language. Real-time updates from the SEC’s EDGAR system help users see new filings as they appear, while AI analysis highlights important changes in financial metrics, business priorities, and risk disclosures. Investors can also review insider-related filings such as Form 4 to monitor transactions by directors and officers in ACAD stock.
By combining original SEC documents with automated explanations, this filings page helps users quickly identify what Acadia is reporting about its financial condition, commercial performance, and development programs in neurological and rare diseases.
ACADIA PHARMACEUTICALS Chief Executive Officer Catherine Owen Adams reported routine equity transactions linked to restricted stock unit vesting. On March 24, 2026, she exercised 23,509 restricted stock units, receiving the same number of common shares at a $0.00 conversion price and increasing her direct common stock holdings to 26,444 shares.
On March 25, 2026, she made an open-market sale of 11,641 common shares at $21.47 per share. Footnotes state these mandatory sales were to cover withholding taxes and related items in connection with restricted stock unit vesting and are intended to comply with Rule 10b5-1(c). Following the sale, she directly holds 14,803 common shares and 70,530 restricted stock units, which vest in four equal annual installments beginning March 24, 2026.
ACADIA Pharmaceuticals EVP Elizabeth H.Z. Thompson reported routine equity compensation activity. On March 24, 2026, she acquired 6,715 shares of common stock at $0.00 per share upon vesting of restricted stock units, increasing her direct holdings to 6,715 shares and 20,146 restricted stock units. On March 25, 2026, 3,435 shares were sold at $21.47 per share to cover withholding taxes and related items under a Rule 10b5-1 arrangement, leaving her with 3,280 common shares directly. The restricted stock units vest in four equal annual installments beginning March 24, 2026.
ACADIA PHARMACEUTICALS executive vice president and chief legal officer Jennifer J. Rhodes exercised 7,515 restricted stock units into the same number of common shares at a conversion price of $0.00 per share. The next day, she sold 3,844 common shares at $21.47 per share.
According to the disclosure, these sales were mandatory and made solely to cover withholding taxes and related tax items tied to the RSU vesting, and are intended to comply with Rule 10b5-1(c). After the sale, Rhodes directly holds 11,280 common shares.
ACADIA PHARMACEUTICALS’ principal accounting officer, James Kihara, reported routine equity compensation activity and related share sales. He exercised or converted a total of 3,769 restricted stock units into common stock at a conversion price of $0.0000 per share, each unit representing one share of common stock.
Across March 24–26, 2026, he disposed of 1,942 shares of common stock in transactions coded as open‑market sales at prices between $21.47 and $21.7253 per share. A footnote explains these mandatory sales were made to cover withholding taxes and related tax items in connection with vesting of restricted stock units and were intended to meet Rule 10b5‑1(c) requirements. After these transactions, Kihara directly holds 26,885 shares of common stock and 4,883 restricted stock units that vest annually in four equal installments starting on March 24, 2026 and March 25, 2025.
ACADIA PHARMACEUTICALS EVP and CFO Mark C. Schneyer reported a combination of equity vesting and related share sales. On March 24 and 25, 2026, he exercised restricted stock units into a total of 14,316 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings.
On March 25 and 26, 2026, he sold an aggregate 7,385 shares of common stock in open-market transactions at prices around $21.47–$21.72 per share. A footnote states these mandatory sales were made to cover withholding taxes and related items in connection with the RSU vesting and are intended to comply with Rule 10b5-1. Following these transactions, he directly holds 60,269 shares of common stock.
The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A reporting that it beneficially owns 0 shares of ACADIA Pharmaceuticals Inc. common stock, representing 0% of the class. The filing explains this reflects an internal realignment and the disaggregated reporting of certain Vanguard subsidiaries under SEC Release No. 34-39538 (January 12, 1998). The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
ACADIA PHARMACEUTICALS director Jonathan Poole received new equity awards as part of his compensation. On March 3, 2026, he was granted 7,482 director stock options with a $22.50 exercise price that vest in equal annual installments over three years, and 3,565 additional options at the same exercise price that vest quarterly over one year, with the final tranche vesting on the earlier of one year after grant or the next annual stockholder meeting. He was also granted 4,218 restricted stock units that vest in equal annual installments over three years and 2,010 restricted stock units that vest in full on the earlier of one year after grant or the next annual stockholder meeting. Each restricted stock unit represents the right to receive one share of common stock upon vesting.
ACADIA PHARMACEUTICALS INC director Jonathan Poole filed an initial ownership report on Form 3. This filing establishes his status as a director and brings his holdings under the SEC's insider reporting framework, but it does not report any share purchases, sales, or other transactions.
ACADIA PHARMACEUTICALS INC reported equity awards to its Principal Accounting Officer, James Kihara. He received a stock option for 21,766 shares of common stock at an exercise price of $22.16 per share and 6,332 restricted stock units, both as compensation-related grants.
According to the terms, 25% of the option vests and becomes exercisable on March 6, 2027, with the remaining shares vesting in 36 equal monthly installments after that date. The restricted stock units vest in four equal annual installments beginning March 6, 2027, each unit representing the right to receive one share of common stock. These are routine compensation awards, not open‑market purchases or sales.
ACADIA PHARMACEUTICALS INC executive Jennifer J. Rhodes, EVP and Chief Legal Officer, received new equity compensation awards. She was granted a stock option for 90,691 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. Twenty‑five percent of this option vests on March 6, 2027, with the remainder vesting in 36 equal monthly installments thereafter. She also received 26,382 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These are compensation grants and do not reflect any open‑market buying or selling.